Galectin-1 (Gal-1), a homodimeric prototype of the galectins with a single carbohydrate-recognition domain, was recently identified as being overexpressed in tumorassociated capillary endothelial cells. The role of Gal-1 in endothelial cellular functions and the mechanism of action of Gal-1 remain unknown. Neuropilin-1 (NRP1) is a neuronal receptor that mediates repulsive growth cone guidance, and NRP1 functions in endothelial cells as a coreceptor (with vascular endothelial growth factor receptors (VEGFRs)) for VEGF 165 . In this study, we found that Gal-1 was overexpressed in the tumorassociated endothelial cells of oral squamous cell carcinomas (Po0.001). Gal-1 increased the proliferation and adhesion of endothelial cells, and enhanced cell migration in combination with VEGF 165 . Surprisingly, Gal-1 selectively bound NRP1 via the carbohydrate-recognition domain, but did not bind VEGFR-1, VEGFR-2 or VEGFR-3. The Gal-1-NRP1 interaction mediated the migration and adhesion of endothelial cells. The binding of Gal-1 to NRP1 enhanced VEGFR-2 phosphorylation and stimulated the activation of the mitogen activated protein (MAP) kinases SAPK1/JNK (stress activated protein kinase-1/c-Jun NH2-terminal kinase). These findings show, for the first time, that Gal-1 can directly bind to NRP1 on endothelial cells, and can promote the NRP1/ VEGFR-2-mediated signaling pathway as well as NRP1-mediated biological activities. Oncogene (2008) 27, 3746-3753; doi:10.1038/sj.onc.1211029; published online 28 January 2008
Keywords: galectin-1; neuropilin-1; endothelial cells; oral cancer
Galectin-1 (Gal-1) is a homodimeric animal lectin with a conserved carbohydrate-recognition domain and binding affinity for b-galactosides. Because Gal-1 interacts with specific glycoconjugates, it has been implicated in several biological processes, including cell proliferation, cell adhesion, apoptosis, metastasis and immunoregulation (Rabinovich, 2005; Camby et al., 2006) . Immunohistochemical staining of Gal-1 in clinical cancer samples revealed that Gal-1 expression was positively associated with the malignant progression of many tumor types such as a malignant glioma, prostate cancer and oral squamous cell carcinoma (Rorive et al., 2001; van den Brule et al., 2001; Chiang et al., 2007) . The high expression of Gal-1 in tumor-associated vascular endothelial cells (TAVECs) was identified in cases of prostate cancer, colon carcinoma and Ewing sarcoma (Clausse et al., 1999; Thijssen et al., 2006) , and Gal-1 expression levels were significantly correlated with prostate tumor aggressiveness (Clausse et al., 1999) .
TAVECs are major components of tumor angiogenesis, and these cells overexpress specific receptors that mediate angiogenic signals required for their survival, growth, migration and differentiation. The Gal-1 overexpressed in TAVECs mediates the adhesion of carcinoma cells to vascular endothelial cells (ECs) and inhibits T-cell transendothelial migration (Glinsky et al., 2000; He and Baum, 2006) . A recent study has reported that expression knockdown of Gal-1 in ECs inhibits cell proliferation and migration (Thijssen et al., 2006) . Only small numbers of microvessels were observed in tumors of Gal-1-null mice, indicating that Gal-1 is crucial for tumor angiogenesis (Thijssen et al., 2006) . Gal-1 can bind to cell-surface receptors such as integrins (Fischer et al., 2005) and several cluster of differentiation (CD) receptors (Elola et al., 2005) , and to extracellular matrix components fibronectin and laminin (Gu et al., 1994) , to exert its functions extracellularly. More recently, studies have shown that various glycosylation patterns of cell surface glycoproteins on different types of T-helper and cancer cells modulate the susceptibility of these cells to Gal-1-induced apoptosis (Toscano et al., 2007; Valenzuela et al., 2007) . It is not clear, however, how the EC effects described above are achieved, and the molecular mechanism by which Gal-1 modulates tumor neovascularization remains to be clarified.
In oral squamous cell carcinoma (OSCC), we first found that Gal-1 was overexpressed in OSCC-associated microvascular endothelial cells and their surrounding extracellular matrix, compared with adjacent healthy cells (Figure 1 ). Gal-1 immunostaining was evaluated in 46 oral squamous cell carcinomas (Table 1) . Staining of Gal-1 in cancer-associated endothelial cells was significantly more pronounced than in matched adjacent nontumor mucosa vascular endothelial cells (two-tailed Fisher's Exact Test, Po0.001). Elevated expression of Gal-1 has been reported in tumor-associated stroma from prostate (van den Brule et al., 2001) , breast (Jung et al., 2007) and oral carcinomas (Chiang et al., 2007) . Therefore, we further investigated the extracellular functions of Gal-1, and explored the molecular pathway by which Gal-1 affects ECs. As shown in Figure 2a , Gal-1 promoted human umbilical vein endothelial cell (HUVEC) proliferation in a dose-dependent manner, but a high concentration of Gal-1 slightly decreased cell growth at 48 and 72 h. Gal-1 also induced HUVEC migration, and this was dependent on carbohydrate recognition. Interestingly, Gal-1 and VEGF 165 exhibited an enhanced effect on cell migration (Figure 2b ). Gal-1 and VEGF 165 had only an additive effect, however, and not a synergistic interaction, when HUVEC proliferation was studied.
Previous studies have demonstrated that Gal-1 binds to poly-N-acetyllactosamine chains in the extracellular matrix, thereby modulating cell adhesion in processes such as tumor invasion and metastasis (Zhou and Cummings, 1993; Ozeki et al., 1995) . In this study, we also examined the role of Gal-1 in the direct adhesion of HUVECs. HUVECs were plated into the wells of polyvinyl microtiter plates that had been precoated either with Gal-1 or with various other known extracellular matrix proteins. As shown in Figure 2c , HUVECs adhered to Gal-1 better than to fibronectin, and as well as they adhered to laminin. The adherence of HUVECs to laminin was significantly increased by stimulation of extracellular Gal-1 and dramatically decreased by Gal-1 expression silencing.
Furthermore, stimulation of ECs with cytokines leads to changes in the expression of cellular anticoagulant and procoagulant cofactors, and results in changes in EC coagulant properties. Tissue factor (TF), a membrane-bound glycoprotein that initiates blood coagulation by allosteric activation of coagulation factor VII, has been shown to be upregulated on the luminal endothelial surface by cytokines such as VEGF 165 , causing rapid intravascular coagulation (Konigsberg et al., 2001) . We therefore determined if Gal-1 might stimulate TF production. We found that although the responses of cells to Gal-1 were similar to the responses seen when VEGF 165 was employed, Gal-1 did not stimulate TF expression (Figure 2d ).
To better understand the function of Gal-1 and the pathways in which it is involved, we sought to isolate proteins from the cell surface of HUVECs that might interact with Gal-1. Specific binding of FITC-labeled Gal-1 to HUVECs was determined using a whole cell binding assay. Dissociation constants (K D ) derived from saturation isotherms are given in Figure 3a . Analysis of the saturation data indicated that a two-site model fitted the data significantly better than a one-site model, with K D values of 125 ± 23 and 3.52 ± 0.18 mM.
Vascular endothelial growth factor receptors (VEGFRs), including VEGFR-1, VEGFR-2, VEGFR-3 and neuropilins, are key mediators of angiogenesis and lymphangiogenesis (Ferrara et al., 2003) , and are all glycoproteins. VEGFR glycosylation is important for the expression and activation of functional VEGFRs (Vaisman et al., 1990; Shintani et al., 2006) . Therefore, we analysed whether Gal-1 modulates EC activities through interactions with VEGFRs. Surface plasmon resonance was used to measure real-time association and dissociation of the binding of Gal-1 to VEGFRs. We tested the binding of four recombinant chimeric Figure 1 The expression of galectin-1 (Gal-1) is upregulated in tumor-associated vascular endothelial cells and the surrounding extracellular matrix. Representative immunohistochemical analysis of Gal-1 expression in oral squamous cell carcinoma (OSCC) tissue (b), and adjacent healthy oral mucosa tissue (a). Serial 5 mm histological sections were immunohistochemically stained using polyclonal anti-human Gal-1 antibody, with heat-induced epitope retrieval. Immunobinding was detected using a streptavidin-biotin-peroxidase complex (DAKO Corporation, Carpinteria, CA, USA) and the chromogen was 3 0 -3-diaminobenzene (0.025%). For the negative control, the primary antibody was omitted (c). Black arrows and white arrows indicate vascular endothelial cells in normal tissues and OSCC tissues, respectively. Scale bar: 25 mm. a The percent of positively stained cells was assigned scores as follows: 0, o5% of cell stained; +, 5-25%; ++, 26-50%; +++, >50%.
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VEGFRs including VEGFR-1/Fc, VEGFR-2/Fc, VEGFR-3/Fc and NRP1/Fc proteins, to immobilized Gal-1. Remarkably, only Neuropilin-1 (NRP1) bound immobilized Gal-1 in a dose-dependent manner, and vice versa. Typical superimposed sensorgrams for various concentrations of Gal-1 binding to an NRP1-immobilizing sensor chip are shown in Figure 3b . Gal-1 could specifically bind to NRP1 with measurable association (k a ca. 1.65 Â 10 5 M À1 s À1 ) and dissociation (k d ca. 0.018 s À1 ) rate constants, and the interaction was of high affinity (average dissociation constant (K D ) ca. 109±31 nM). The binding of Gal-1 to NRP1 was completely blocked by 50 mM lactose. No binding of VEGFR-2 or VEGFR-3 to immobilized Gal-1 was observed (Supplementary Figure S1a) . Although VEGFR-1 was found to bind weakly to immobilized Gal-1, we detected no Gal-1 binding to a sensor chip onto which VEGFR-1 had been immobilized (Supplementary Figure S1b ).
To further confirm the binding of Gal-1 to NRP1, FITC-labeled rh-Gal-1 was used as a probe to identify Gal-1-binding proteins in HUVECs, using the Farwestern technique. As shown in Figure 3c , the results demonstrated the existence of two major bands (ca. 150 and 130 kDa) and four minor bands (ca. 110, 100, 80 and 65 kDa) binding to Gal-1; these bands were not seen when Gal-1 protein was absent (left panel). Interestingly, in the same experiment, the Gal-1 binding pattern observed in extracts from NRP1 siRNA-transfected HUVECs was markedly reduced compared with the control (Figure 3c , middle panel, indicated with an arrowhead). The difference in binding patterns noted in 0 -UGAUGCACACCUCUG CAACACUUCC, synthesized by Invitrogen, Carlsbad, CA, USA), using the RNAiFect transfection reagent (Qiagen, Valencia, CA, USA) for 24 h. Western blotting for Gal-1 was used to confirm the silencing effect (data are shown in the insert). Control or Gal-1-silenced HUVECs were allowed to adhere to wells coated with various proteins (10 mg ml
À1
) for 6 h. The attached cells were stained with crystal violet, and absorbances at 595 nm were measured. (d) Gal-1 did not affect tissue factor expression of HUVECs. For the tissue factor expression assay, HUVECs were plated, grown to near-confluence and preincubated for 12 h under serum-reduced (0.5% (v/v) fetal bovine serum) conditions, followed by stimulation with VEGF 165 or Gal-1. After 8 h, HUVECs were harvested and lysed with 0.5% (v/v) Triton X-100 in phosphate-buffered saline (PBS). Total tissue factor expression was detected using a 'Tissue Factor ELISA KIT' (American Diagnostica, Greenwich, CT, USA). Results in the figure show the mean ± s.d. of three independent experiments, performed in triplicate. The significance of differences between groups was evaluated with the Student's t-test. *Po0.05; **Po0.01.
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SH Hsieh et al NRP1 expression knockdown cells revealed that NRP1 was capable of interacting with Gal-1. Flow cytometric analysis was performed to demonstrate that Gal-1 bound HUVECs through an interaction with NRP1. Gal-1 dose-dependently bound to HUVECs, and the binding was almost completely abrogated by 10 mM lactose (Figure 3d ). We also measured the capacity of Gal-1 to bind to HUVECs transfected with NRP1 siRNA and found that NRP1-depleted cells showed a significantly reduced capacity (geometric mean reduction 38%, Po0.01) to bind to Gal-1, compared with control cells (Figure 3d ). Taken together, these data directly demonstrate a preferential, and relatively high affinity, binding of Gal-1 to NRP1 on ECs. Further, NRP1 immunohistochemical staining of clinical OSCC tissue specimens was explored. We found that the expression of NRP1 in OSCC-associated microvascular endothelial cells was higher than that in adjacent healthy endothelial cells (Supplementary Figure S2) . Further studies are required to verify the Figure 3 Neuropilin-1 (NRP1) is a galectin-1 (Gal-1) receptor on human umbilical vein endothelial cells (HUVECs). (a) Scatchard plot of fluorescein isothiocyanate-labeled rh-Gal-1 binding to HUVECs. Rh-Gal-1 was labeled using a FITC protein labeling kit (Pierce, Rockford, IL, USA). HUVECs were plated in 96-well plates at 2 Â 10 4 cells per well and incubated with various concentrations of FITC-Gal-1 (2.5-500 nM) for 4 h at 4 1C. After removing unbound proteins by repeated washing, the fluorescence intensity of bound FITC-Gal-1 was measured using a Perkin Elmer Wallac Victor 1420 Multilabel counter. Nonspecific binding was determined in the presence of a 10-fold excess of unlabeled rh-Gal-1. The Scatchard plot was drawn from the saturation experiment shown in the insert, and constructed using nonlinear regression analysis. The dashed lines represent the high-affinity and low-affinity binding components for FITC-Gal-1. (b) Surface plasmon resonance analysis of Gal-1 binding to immobilized NRP1. A Biacore X machine (Biacore AB, Uppsala, Sweden) was used to analyse the binding kinetics of Gal-1 to NRP1. A recombinant NRP1/Fc chimeric protein (R&D Systems, Minneapolis, MN, USA) was immobilized on CM5 sensor chips, by amine coupling, according to the manufacturer's instructions. The four concentrations of Gal-1 (top to bottom: 280, 140, 70 and 280 nM plus 50 mM lactose) were injected at a flow rate of 10 ml min À1 in HBS-P buffer onto a chip containing 3000 resonance units (RU) of NRP1 at time zero. The resulting sensorgrams are superimposed, and the binding kinetics from two independent experiments were averaged and analysed using BIAevaluation software, version 3.0. (c) Left panel: Far-western blot analysis of Gal-1 bound to HUVEC proteins. Fifteen micrograms amounts of HUVEC cellular protein/lane were subjected to 10% (w/v) acrylamide SDS-PAGE and transferred to PVDF membranes. After blocking with 5% (w/v) nonfat dry milk in TBST, the membranes were incubated with or without rh-Gal-1 (10 mg ml À1 ) in TBST for 18 h at 4 1C. The Gal-1 protein was detected using polyclonal anti-Gal-1 and revealed by HRP-coupled goat anti-rabbit antibodies. Middle panel: Farwestern blot analysis of Gal-1 bound to NRP-1-silenced HUVECs. Cells were transfected with 20 nM of NRP1-siRNA or a control nonsilencing siRNA (si-NRP1: 5 0 -AACAGCCUUGAAUGCACUUAU, si-C: 5 0 -AAUUCUCCGAACGUGUCACGU, both synthesized by Qiagen) for 24 h and total protein lysates were then extracted for Far-western analysis. Right panel: western blotting for NRP1 (using polyclonal Ab C-19, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used to confirm the silencing effect. correlation between Gal-1 and NRP1 expression in oral cancers in vivo.
To examine whether NRP1 might mediate the Gal-1-modulated biological activities of HUVECs, cells were transfected with NRP1-specific or a scrambled siRNA. As shown in Figure 4a , knockdown of NRP1 completely abolished Gal-1-induced HUVEC migration, but had only a marginal effect on Gal-1-induced HUVEC proliferation. Silencing of NRP1 expression also led to a marked decrease in the adhesion of HUVECs to Gal-1 (Figure 4b) , and significantly decreased EC attachment to laminin and fibronectin, a result that is consistent with the reported decrease in the adhesive ability to the extracellular matrix of HUVECs transfected with NRP1 siRNA (Murga et al., 2005) . As described earlier, Gal-1 binds both a 7 b 1 and a 5 b 1 integrins, and regulates smooth muscle cell differentiation and tumor cell growth (Gu et al., 1994; Fischer et al., 2005) . We therefore examined the expression levels of several integrins, including a 3 b 1 , a v b 3 and a 5 b 1 , in NRP1-defective and control cells, by flow cytometry, and found that the expression of these integrins was similar in both types of cells (data not shown). These data rule out the possibility that changes in integrin expression in NRP1-silenced cells affected Gal-1-mediated cellular responses, and suggest that NRP1 is directly involved in HUVEC migration and adhesion to Gal-1.
As a receptor for VEGF 165 , NRP1 forms complexes with VEGFR-1 and/or VEGFR-2 to enhance the binding of VEGF 165 to VEGFRs, thus promoting VEGF 165 -mediated angiogenesis, cell migration, and tumorigenicity. NRP1 can facilitate the binding of VEGF 165 to VEGFR-2, enhance VEGFR-2 phosphorylation, and potentiate VEGF 165 activities in ECs (Neufeld et al., 2002) . Hence, we investigated whether VEGFR-2 phosphorylation and downstream pathway activation were involved in NRP1-mediated Gal-1 activities. As shown in Figure 4c , stimulation with a high concentration of Gal-1 induced phosphorylation of VEGFR-2, which was abrogated in the presence of 10 mM lactose. Gal-1 was unable to induce phosphorylation of VEGFR-1 or VEGFR-3 (Supplementary Figure S3) . To further determine whether VEGFR-2 mediated Gal-1-modulated endothelial cell functions, the effects of VEGFR-2-specific siRNAs on the migration capability of cells were analysed. As shown in Figure 4d , silencing of VEGFR-2 expression by si-RNA-2 apparently suppressed Gal-1-induced HUVEC migration. Reduced expression of VEGFR-2 did not, however, affect the adhesion capacity of endothelial cells to laminin or Gal-1 (Supplementary Figure S4) . These data directly show that the activation of the NRP1/ VEGFR-2 complex is required for Gal-1-induced endothelial cell migration.
The MAPK signaling pathway has been previously shown to be activated by VEGFRs, and this pathway is a critical intracellular mediator of angiogenesis. We next examined signaling pathways downstream of VEGFR-2, to determine which pathway might be involved in the transmittal of activating signals. In HUVECs, Gal-1 stimulated the MAP kinases ERK and JNK, Gal-1-induced ERK activity was stimulated earlier (by 5 min) than Gal-1-induced JNK activity (Figure 4e ). We then examined the role of NRP1 in Gal-1-induced activation of VEGFR-2, ERK and JNK. As shown in Figure 4f , knockdown of NRP1 completely abolished the activation of VEGFR-2 and partially blocked by 50% the phosphorylation of JNK in response to Gal-1. To confirm the role of JNK in Gal-1-modulated EC activities, cells were pretreated with 2.5 mM of a selective JNK inhibitor, SP600125, and migration and adhesion abilities were determined. As shown in Figure 4g , blocking the increase in JNK activity with the JNK inhibitor completely abolished cell migration induced by Gal-1. The ability of endothelial cells to adhere to laminin and Gal-1 was not, however, influenced by the JNK inhibitor (Supplementary Figure S5) . The inhibition of JNK may affect not only Gal-1 signaling, as other pathways may be involved in the activity of JNK. Therefore, further studies are required to clarify the role The effect of NRP1-silencing on HUVEC adhesion. Control or NRP1-silenced HUVECs were analysed for adhesion abilities in wells coated with various proteins as described in the legend to Figure 2c . (c) Gal-1 induced phosphorylation of vascular endothelial growth factor receptors (VEGFR)-2. After 24 h of starvation, HUVECs were treated with 1 nM VEGF or rh-Gal-1 for 5 min, and the cells were then immediately solubilized with lysis buffer. Activation of VEGFR-2 was determined by immunoblotting cell extracts with anti-phospho-VEGFR-2 antibodies (pTyr1214; Calbiochem, San Diego, CA, USA). Total VEGFR-2 was determined using anti-VEGFR-2 antibodies (sc-504, Santa Cruz Biotechnology). (d) VEGFR-2 is required for Gal-1-induced HUVEC migration. Three individual VEGFR-2 specific siRNAs were transfected into endothelial cells to knock down VEGFR-2 expression (si-KDR-2, 5 0 -UAAACAGGAGGAGAGCUCAGUGUGG, synthesized by Invitrogen). Western blotting for VEGFR-2 was used to confirm the silencing effect; the data are shown in the insert. Control (si-C) or VEGFR-silenced (si-KDR-2) HUVECs were used to analyse migration capacities. (e) Time course of Gal-1-induced ERK and JNK phosphorylation. HUVECs were treated with 0.25 mM rh-Gal-1 for various time periods and then immediately solubilized for western analysis. The following antibodies were used: rabbit anti-total ERK-1/-2 (catalog 9102; Cell Signaling, Beverly, MA, USA), mouse anti-phospho-ERK-1/-2 (9106; Cell Signaling), rabbit anti-total JNK-1/-2 (9258; Cell Signaling) or rabbit anti-phospho-c-JNK-1/-2 (9255; Cell Signaling). (f) The effect of NRP1-silencing on the Gal-1-induced phosphorylation of VEGFR-2, ERK and JNK. HUVECs were transfected with nonsilencing or NRP1 siRNA for 24 h. After transfection, cells were serum-starved for 24 h, treated with 0.25 mM rh-Gal-1 for 10 min, and immediately solubilized for western analysis. (g) Inhibition of JNK activation suppressed Gal-1-induced HUVEC migration. HUVECs were seeded onto transwells and treated with 2.5 mM of the JNK inhibitor, SP600125, for 15 min. Gal-1 was then added to 0.5 mM and the migration assay was performed at 37 1C for 16 h.
SH Hsieh et al of JNK in Gal-1-modulated biological activities. Taken together, our results suggest that NRP1 is required for the signal transduction of Gal-1-induced biological activities. In this study, NRP1 was first identified as a high affinity binding site for Gal-1 on ECs, and it was then shown that NRP1 mediated Gal-1-promoted migration of ECs. Several approaches indicated that Gal-1 can preferentially and specifically bind NRP1. Whole EC binding studies were conducted, and saturation isotherms obtained using FITC-labeled Gal-1 indicated that the binding of Gal-1 to ECs is specific and dependent on carbohydrate recognition. Scatchard plot analysis suggested that there were at least two forms of cellular receptors for Gal-1, one of high affinity and the other of lower affinity. Surface plasmon resonance was used to show that Gal-1 could specifically bind to NRP1, with high affinity. This conclusion was further supported by flow cytometry and Far-western analysis in NRP1-silenced ECs. Various membrane glycoproteins have been identified as binding partners of Gal-1. These include integrin a5b1, which has recently been shown to interact with Gal-1 expressed by several cancer cells, and a5b1 was required for Gal-1-induced growth inhibition (Fischer et al., 2005) . Integrin a5b1 is selectively expressed in angiogenic vasculature during tumor progression and is a potential target for diagnostics and therapeutics (Parsons-Wingerter et al., 2005) . Our Far-western blot analysis revealed the existence of several proteins on ECs that bound to Gal-1 (Figure 3c ). It is possible that some Gal-1-binding proteins on ECs contribute the low affinity binding sites, and that one of the Gal-1-binding proteins may be integrin a5. This idea deserves further experimental confirm.
Our results indicate that extracellular Gal-1 promotes the proliferation, migration, and adhesion of HUVECs, suggesting an important role for Gal-1 in tumor angiogenesis. Gal-1 functions as an endothelial cell migration enhancer via NRP1 binding, VEGFR-2 activation, and modulation of the JNK signaling pathways. Silencing of VEGFR-2 expression and inhibition of JNK activation have only minimal effects, however, on the adhesion capacity of endothelial cells to Gal-1 (Supplementary Figures S4 and S5 ). Previous studies have reported that NRP1 alone can mediate HUVEC adhesion in a VEGFR-2-independent manner (Murga et al., 2005) . Additional studies will be required to clarify the mechanisms of action of NRP1 in Gal-1-enhanced endothelial cell adhesion.
NRP1 is a type I transmembrane glycoprotein and is expressed in metastatic tumor cells, tumor-associated stromal cells, the tips of actively growing neuronal axons and mesenchymal stem cells (Neufeld et al., 2002; Fons et al., 2004; Hong et al., 2007) , as well as in ECs. The NRP1 signaling induced by semaphorin 3A causes the repulsion of growing axons, proapoptosis and antimigration effects in tumor cells and ECs, whereas VEGF antagonizes these effects by promoting cell proliferation and survival (Castro-Rivera et al., 2004) . A recent study has shown that NRP1 promotes human glioma cell survival by modulating an HGF/SF autocrine pathway (Hu et al., 2007) . In this study, Gal-1 was identified as a novel NRP1 ligand, and Gal-1 modulated NRP1-mediated EC functions. This finding, together with the fact that high-level Gal-1 expression is also observed in regenerative axon tips (Gaudet et al., 2005) , tumor stromal cells and mesenchymal stem cells (Kadri et al., 2005) , implies that the involvement of Gal-1 in several cellular responses is dependent on signals delivered after Gal-1 interaction with NRP1. Taking these data together, the coexpression of Gal-1 and NRP1 may create a novel interacting signal that modulates NRP1-mediated neuron regeneration, angiogenesis and tumor metastasis. The findings presented here open the way for further investigation of such possibilities, and offer new insights into the role of Gal-1 in NRP1-associated biological processes.
